Autor: |
Ojo OO, Srinivasan DK, Owolabi BO, Flatt PR, Abdel-Wahab YH; School of Biomedical Sciences, University of Ulster, Coleraine, BT52 1SA, Northern Ireland, UK. y.abdel-wahab@ulster.ac.uk. |
Jazyk: |
angličtina |
Zdroj: |
Protein and peptide letters [Protein Pept Lett] 2014; Vol. 22 (3), pp. 256-63. |
DOI: |
10.2174/0929866521666141229105757 |
Abstrakt: |
Earlier peptidomic analysis of the skin secretion of Xenopus amieti led to the identification of orthologs of magainins and other peptides. This study investigated the degradation, in vitro insulin-releasing and acute metabolic effects of magainin-AM1 (GIKEFAHSLGKFG KAFVGGILNQ) and magainin-AM2 (GVSKILHSAGKFGKAFLGEIMKS). Plasma degradation was investigated using reversed-phase HPLC and MALDI-TOF mass spectroscopy. Insulin-releasing effects were determined using BRIN-BD11 clonal beta cells and mouse islets. Effects of magainin peptides on cytosolic enzyme lactate dehydrogenase release, membrane potential and intracellular Ca(2+) concentration were assessed using BRIN-BD11 cells while their in vivo effects on glucose tolerance and insulin release were assessed in obese, insulin-resistant Swiss National Institute of Health (NIH) mice. Both peptides were resistant to degradation by plasma enzymes in vitro for up to 8 h. Though magainin-AM1 elicited non-toxic, concentration-dependent stimulation of insulin-release from clonal BRINBD11 cells at concentrations ≥ 100nM, magainin-AM2 produced a higher stimulation of insulin-release from BRIN-BD11 cells and isolated mouse islets. Membrane depolarization and intracellular [Ca(2+)]i in BRIN-BD11 cells were significantly (P<0.05) induced by both peptides and chelation of extracellular Ca(2+), addition of diazoxide or verapamil significantly (P<0.01) reduced the insulinotropic actions of the peptides. Administration of magainin-AM2 (75 nmol/kg body weight) to high-fat fed mice significantly enhanced insulin-release (P<0.01) and improved glucose tolerance (P<0.05). These data indicate magainin-AM2 peptides have potential for development into agents for treatment of type 2 diabetes. |
Databáze: |
MEDLINE |
Externí odkaz: |
|